Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Oct;66(4):692–697. doi: 10.1038/bjc.1992.339

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.

F A MacNeill 1, A L Jones 1, S Jacobs 1, P E Lønning 1, T J Powles 1, M Dowsett 1
PMCID: PMC1977412  PMID: 1419608

Abstract

The influence of the prototype aromatase inhibitor Aminoglutethimide (AG) and its analogue Rogletimide (RG) on peripheral aromatisation were investigated in 13 postmenopausal women with advanced breast cancer. Seven patients received AG 1,000 mg daily plus Hydrocortisone (HC) cover and six received RG as dose escalation of 200 mg bd, 400 mg bd and 800 mg bd. In vivo aromatase inhibition was investigated using the double bolus injection technique with [4-14C] oestrone ([4-14C]E1) and [6,7-3H] androstenedione ([6,7-3H]4A) followed by a 96 h urine collection. The labelled urinary oestrogens were separated and purified by chromatography and HPLC. Plasma oestradiol (E2) was also measured. AG mean aromatase inhibition was 90.6% +/- 1.8 s.e.m. and E2 suppression 75.7% +/- 7.3 s.e.m. RG mean aromatase inhibition was 50.6% +/- 9.8 s.e.m. at 200 mg bd, 63.5% +/- 5.7 s.e.m. at 400 mg bd and 73.8% +/- 5.8 s.e.m. at 800 mg bd. E2 suppression was 30.7% +/- 9.5 s.e.m., 40.2% +/- 10.3 s.e.m. and 57.6% +/- 9.2 s.e.m. respectively. These results confirm the efficacy of AG as an aromatase inhibitor. RG produced dose dependent E2 suppression and aromatase inhibition, but even at the maximum tolerated dose of 800 mg bd had sub-optimal aromatase inhibition and oestradiol suppression compared with AG.

Full text

PDF
692

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dowsett M., Cunningham D. C., Stein R. C., Evans S., Dehennin L., Hedley A., Coombes R. C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 1989 Mar 1;49(5):1306–1312. [PubMed] [Google Scholar]
  2. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  3. Dowsett M., MacNeill F., Mehta A., Newton C., Haynes B., Jones A., Jarman M., Lonning P., Powles T. J., Coombes R. C. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer. 1991 Nov;64(5):887–894. doi: 10.1038/bjc.1991.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dowsett M., Stein R. C., Mehta A., Coombes R. C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol (Oxf) 1990 May;32(5):623–634. doi: 10.1111/j.1365-2265.1990.tb00906.x. [DOI] [PubMed] [Google Scholar]
  5. Foster A. B., Jarman M., Leung C. S., Rowlands M. G., Taylor G. N., Plevey R. G., Sampson P. Analogues of aminoglutethimide: selective inhibition of aromatase. J Med Chem. 1985 Feb;28(2):200–204. doi: 10.1021/jm00380a009. [DOI] [PubMed] [Google Scholar]
  6. Goss P. E., Powles T. J., Dowsett M., Hutchison G., Brodie A. M., Gazet J. C., Coombes R. C. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res. 1986 Sep;46(9):4823–4826. [PubMed] [Google Scholar]
  7. Grodin J. M., Siiteri P. K., MacDonald P. C. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973 Feb;36(2):207–214. doi: 10.1210/jcem-36-2-207. [DOI] [PubMed] [Google Scholar]
  8. Harris A. L., Cantwell B. M., Dowsett M. High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. Br J Cancer. 1988 Oct;58(4):493–496. doi: 10.1038/bjc.1988.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Haynes B. P., Jarman M., Dowsett M., Mehta A., Lønning P. E., Griggs L. J., Jones A., Powles T., Stein R., Coombes R. C. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol. 1991;27(5):367–372. doi: 10.1007/BF00688859. [DOI] [PubMed] [Google Scholar]
  10. Jacobs S., Lønning P. E., Haynes B., Griggs L., Dowsett M. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhib. 1991;4(4):315–325. doi: 10.3109/14756369109030396. [DOI] [PubMed] [Google Scholar]
  11. Jacobs S., MacNeill F., Lonning P., Dowsett M., Jones A., Powles T. Aromatase activity, serum oestradiol and their correlation with demographic indices. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):769–771. doi: 10.1016/0960-0760(92)90421-e. [DOI] [PubMed] [Google Scholar]
  12. Leung C. S., Rowlands M. G., Jarman M., Foster A. B., Griggs L. J., Wilman D. E. Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents. J Med Chem. 1987 Sep;30(9):1550–1554. doi: 10.1021/jm00392a004. [DOI] [PubMed] [Google Scholar]
  13. Lønning P. E., Jacobs S., Jones A., Haynes B., Powles T., Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer. 1991 May;63(5):789–793. doi: 10.1038/bjc.1991.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lønning P. E., Johannessen D. C., Thorsen T., Ekse D. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. J Steroid Biochem. 1989 Oct;33(4A):541–545. doi: 10.1016/0022-4731(89)90039-3. [DOI] [PubMed] [Google Scholar]
  15. Lønning P. E., Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs. 1988 Jun;35(6):685–710. doi: 10.2165/00003495-198835060-00005. [DOI] [PubMed] [Google Scholar]
  16. Lønning P. E., Kvinnsland S., Thorsen T., Ueland P. M. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clin Pharmacokinet. 1987 Dec;13(6):393–406. doi: 10.2165/00003088-198713060-00004. [DOI] [PubMed] [Google Scholar]
  17. Lønning P. E., Skulstad P. Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. J Steroid Biochem. 1989 Oct;33(4A):565–571. doi: 10.1016/0022-4731(89)90042-3. [DOI] [PubMed] [Google Scholar]
  18. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978 Dec;47(6):1257–1265. doi: 10.1210/jcem-47-6-1257. [DOI] [PubMed] [Google Scholar]
  19. Santner S. J., Leszczynski D., Wright C., Manni A., Feil P. D., Santen R. J. Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Res Treat. 1986;7(1):35–44. doi: 10.1007/BF01886734. [DOI] [PubMed] [Google Scholar]
  20. Stein R. C., Dowsett M., Davenport J., Hedley A., Ford H. T., Gazet J. C., Coombes R. C. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res. 1990 Mar 1;50(5):1381–1384. [PubMed] [Google Scholar]
  21. Stein R. C., Dowsett M., Hedley A., Davenport J., Gazet J. C., Ford H. T., Coombes R. C. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother Pharmacol. 1990;26(1):75–78. doi: 10.1007/BF02940300. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES